Activity from announced rounds
Alpha Wave is the investment-manager name used in the covered financings and connected to Alpha Wave Global’s official press and investment records.
The recorded activity includes a lead role in Moonwalk Biosciences’ Series B for medicines targeting fat-tissue pathways in obesity and cardiometabolic disease. Other announcements concern AdvanCell’s targeted alpha radiopharmaceuticals for cancer and Ultrahuman’s wearable ring and health-testing products. These events describe the activity captured here rather than the manager’s complete allocation.
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
Ultrahuman combines a wearable ring with app-based health insights and complementary testing.
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.